Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Investigator-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease

NCT05496374 is registered in ClinicalTrials.gov with Spero Therapeutics as lead sponsor.

NCT NCT05496374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05496374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Investigator-Blinded, Placebo-Controlled, Multicenter, Phase 2, Dose-Ranging Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease
Lead sponsor
Spero Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2022
Completion date
December 2, 2024
Enrollment
25 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

nontuberculous mycobacterial pulmonary disease (ntm-pd)